First-line chemotherapy for ovarian cancer – the controversy continues
2002
First-line chemotherapy for ovarian cancer – the controversy continues
Editorial
Evidence: moderate
Author Information
Author(s): Kaye S B
Primary Institution: The Royal Marsden Hospital/Institute of Cancer Research
Conclusion
Paclitaxel along with carboplatin remains a reasonable first-line therapy for advanced ovarian cancer, despite ongoing debates about its efficacy.
Supporting Evidence
- Paclitaxel has shown efficacy in patients whose disease no longer responds to platinum.
- Combination chemotherapy has provided significant survival benefits for many cancers.
- The trials GOG 132 and ICON 3 suggest that single-agent platinum therapy may be as effective as combination therapy.
Takeaway
Doctors are still figuring out the best way to treat ovarian cancer, and while some treatments work well, there are questions about whether they are the best choice.
Potential Biases
There may be biases due to the heterogeneity of treated populations and variations in clinical practices.
Limitations
The conclusions drawn from the trials may be affected by differences in treatment protocols and patient populations.
Statistical Information
P-Value
0.06
Confidence Interval
0.70 to 1.01
Statistical Significance
p=0.06
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website